Well look at it this way they providing Avelumab for the study, saving Imugene some $ along the way. The fact that they willing to provide Avelumab free for this study says a lot already as it is a Phase 2 study. Not only are they providing Avelumab, they are also willing to put their name to it and be associated with the study by announcing it to the world.
If this works; we do not even have to imagine what will happen, we know what will happen.
Great result by Leslie and her team once again.
Ann: Clinical Trial Supply Agreement with Merck KGaA and Pfizer, page-42
-
- There are more pages in this discussion • 211 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 94526 | 4.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 22000 | 2 |
View Market Depth
| Last trade - 09.41am 11/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable